Kodu・Aktsiate loetelu・Xencor Inc

Xencor Inc

Suletud

SektorTervishoid

19.36 -0.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.87

Max

19.85

Põhinäitajad
By Trading Economics
Sissetulek	-214M -129M
Müük	-24M 4.5M
Aktsiakasum	-1.71
Kasumimarginaal	-2,854.65
Töötajad	260
EBITDA	-127M -121M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+23.4% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	404M 1.4B
Eelmine avamishind	19.98
Eelmine sulgemishind	19.36

Uudiste sentiment

By Acuity

50%

163 / 340 Pingereas Healthcare

Xencor Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22. juuli 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21. juuli 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20. juuli 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Võrdlus sarnastega

Hinnamuutus

Xencor Inc Prognoos

Hinnasiht

By TipRanks

23.4% tõus

12 kuu keskmine prognoos

Keskmine 24.1 USD 23.4%

Kõrge 38 USD

Madal 13 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Xencor Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Xencor Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

163 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.